• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

    4/6/22 9:59:12 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIXT alert in real time by email
    SC 13G/A 1 sc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)

     

    Lixte Biotechnology Holdings, Inc.

     

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

     

    (Title of Class of Securities)

     

    539319 202

     

    (CUSIP Number)

     

    December 17,2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
       
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall not be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     


    CUSIP NO. 539319 10 3
      Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSONS.

    Eric Forman

     
         
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☒

         
    3.

    SEC USE ONLY

     
     

     

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

     

    5.

     

    SOLE VOTING POWER

     

    104,431(1)

         
    6. SHARED VOTING POWER  
         
    7. SOLE DISPOSITIVE POWER 104,431(1)
         

    8.

    SHARED DISPOSITIVE POWER

     

         
         
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON.

    1104,431(1)

     
         

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

         

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)2

    0.075%

     
         

     

    12.

     

    TYPE OF REPORTING PERSON

     

    IN

     

     

     

    1 Consists of 38,598 shares of Common Stock, warrants to purchase 3,333 shares and options to purchase 62,500 shares of Common Stock, owned directly by Mr. Forman.

    2 Based on 13,746,593 shares of Common Stock, outstanding as of March 11,2022.

     

     

     

     


    CUSIP NO. 539319 10 3
      Page 3 of 5 Pages

     

    Explanatory Note: On December 17,2021, the Reporting Person was replaced as Trustee of the John and Barbara 2015 Trust and is no longer the beneficial owner of the 1,333,333 shares if the Issuer’s Common Stock

     

    Item 1(a). Name of Issuer.

     

    The name of the issuer is Lixte Biotechnology Holdings, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.

     

    The address of the Issuer’s principal executive office is 680 East Colorado Boulevard, Suite 180, Pasadena CA 91101.

     

    Item 2(a). Name of Person Filing.

     

    Eric Forman

     

    Item 2(b). Address of Principal Business Office, or, if None, Residence.

     

    2680 East Colorado Boulevard, Suite 180, Pasadena CA 91101

     

    Item 2(c). Citizenship.

     

    United States citizen.

     

    Item 2(d). Title of Class of Securities.

     

    The title of the class of securities to which this statement relates is the Common stock, $0.0001 par value per share.

     

    Item 2(e). CUSIP No.

     

    The CUSIP number is 539319-202.

     

    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b) or 13d-2(b), Check Whether the Person Filing is a:

     

    (a) ☐ Broker or dealer registered under Section 15 of the Act
         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Act
         
    (c) ☐ Insurance Company as defined in Section 3(a)(19) of the Act
         
    (d) ☐ Investment Company registered under Section 8 of the Investment Company Act of 1940
         
    (e) ☐ Investment Adviser registered under section 203 of the Investment Advisers Act of 1940
         
    (f) ☐ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
         
    (g) ☐ Parent Holding Company, in accordance with Rule 13d-1(b)(1)(ii)(G) (Note: See Item 7)
         
    (h) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(H).

     

     

     

     


    CUSIP NO. 539319 10 3
      Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover pages and is incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5% of the class of securities, check the following ☒

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     


    CUSIP NO. 539319 10 3
      Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: April 06, 2022
         
      /s/ ERIC FORMAN
      Eric Forman

     

     

     

    Get the next $LIXT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LIXT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIXT
    SEC Filings

    View All

    SEC Form PRE 14A filed by Lixte Biotechnology Holdings Inc.

    PRE 14A - NOMAD POWER SOLUTIONS, INC. (0001335105) (Filer)

    7/17/26 5:29:27 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NOMAD POWER SOLUTIONS, INC. (0001335105) (Filer)

    7/10/26 11:43:15 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lixte Biotechnology Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Filer)

    7/2/26 4:00:46 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Stazzone Peter was granted 50,000 shares, increasing direct ownership by 100% to 100,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:18:44 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sawyer Jason David was granted 40,000 shares, increasing direct ownership by 160% to 65,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:16:48 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman of the Board Pursglove Geordan Garrett was granted 350,000 shares, increasing direct ownership by 100% to 700,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    7/2/26 4:13:51 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Energy Pivot Complete: LIXTE Biotechnology Finishes Corporate Rebrand to NOMAD Power Solutions, Begins Trading Under Nasdaq: NMAD

    Issued on behalf of NOMAD Power Solutions, Inc. (NASDAQ:NMAD), formerly LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT)NOMAD Power Solutions, Inc. has completed its corporate name change from LIXTE Biotechnology Holdings, Inc. and begins trading today under the new Nasdaq ticker NMAD, marking its transition into the AI energy infrastructure equipment and services sector following its acquisition of NOMAD Transportable Power SystemsAmerican News Group News CommentaryBOCA RATON, Fla., July 6, 2026 /CNW/ -- The artificial intelligence buildout has run headlong into a physical bottleneck: electricity. Data centers are demanding power faster than the grid can add it through traditional fixed inf

    7/6/26 11:40:00 AM ET
    $FLNC
    $BE
    $GEV
    Industrial Machinery/Components
    Miscellaneous
    Energy
    Biotechnology: Pharmaceutical Preparations

    LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

     -- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. ("NOMAD" or the "Company"), today announced that it has completed its name change from LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) to NOMAD Power Solutions, Inc (NASDAQ:NMAD). The Company’s common stock will begin trading today under its new ticker, NMAD on the Nasdaq Stock Market. Shares under the symbol LIXT ceased trading at the close of market on Thursday, July 2, 2026. The new corporate name reflects the next chapter for the

    7/6/26 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS

    -Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems-                                          -Company Plans Corporate Name Change to NOMAD Power Solutions                                       BOCA RATON, Fla./WATERBURY, Vt., July 02, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) ("LIXTE" or the "Company") today announced it has completed the previously announced merger with NOMAD Transportable Power Systems, Inc. ("NOMAD"), a market leader in deployable, utility-grade battery energy storage systems (BESS), In connection with the merger, the Company is issuing to the

    7/2/26 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 67% to 25,000 units (SEC Form 4) (Amendment)

    4/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:39:03 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Van Der Baan Bastiaan Jeroen bought $28,000 worth of shares (10,000 units at $2.80), increasing direct ownership by 1,000% to 11,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/5/23 8:36:30 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernards Rene bought $24,116 worth of shares (10,000 units at $2.41), increasing direct ownership by 33% to 20,000 units (SEC Form 4)

    4 - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Issuer)

    10/4/23 6:10:01 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Financials

    Live finance-specific insights

    View All

    LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

    BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company's website, www.lixte.com, and on the SEC's website, www.sec.gov. "2025 was a transformative and highly productive year for our Company," said Geordan Pursglove, who was named LIXTE's Chairman and Chief Executive Officer in June 2025. "We strengthened LIXTE's foundation by assembling an

    3/31/26 3:45:00 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

    Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT) a biotech company focused on advancing cancer treatments, today announced it has completed the acquisition of Liora Technologies Europe Ltd., a UK-based company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora will become a wholly owned subsidiary of LIXTE. The acquisition includes Liora's proprietary flagship technology LiGHT Sys

    11/25/25 8:30:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Leadership Updates

    Live Leadership Updates

    View All

    LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

    Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE's Strategic Expansion into AI Energy Infrastructure BOCA RATON, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), today announced its strategic transformation into an AI energy infrastructure equipment & services platform focused on meeting the rapidly growing power demands of AI and hyperscale data centers. In connection with this transformation, Stuart D. Porter, Founder, Managing Partner, Chief Executive Officer and Chief Investment Officer of Denham Capital Managemen

    6/1/26 8:50:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

    BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company's Liora Technologies Europe Ltd. subsidiary ("Liora"). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc. Over his

    2/18/26 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

    -- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced that Lourdes Felix and Guy Primus have joined the Company's Board of Directors, and Peter Stazzone has been named Chief Financial Officer. The Company also announced that it has relocated its corporate headquarters to Boca Raton. The new board members succeed Bas van der Baan, who remains Chief Scientific Officer of LIXTE, and René Bernards, PhD, who has been n

    9/3/25 8:00:00 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LIXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lixte Biotechnology Holdings Inc.

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:58:22 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lixte Biotechnology Holdings Inc. (Amendment)

    SC 13G/A - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    4/6/22 9:59:12 PM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed

    SC 13G - LIXTE BIOTECHNOLOGY HOLDINGS, INC. (0001335105) (Subject)

    3/3/21 7:45:27 AM ET
    $LIXT
    Biotechnology: Pharmaceutical Preparations
    Health Care